Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 vs investigator's choice chemotherapy in HER2-low recurrent/metastatic breast cancer (China, phase III)
CTR20242868Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2102 in breast cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20242868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242868.